Kilitch Drugs (India) Limited (KILITCH.NS)
INR 317.15
(-1.14%)
INR 317.15
(-1.14%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.4 Billion INR | 9.36% |
| 2022 | 2.19 Billion INR | 4.61% |
| 2021 | 2.09 Billion INR | 3.28% |
| 2020 | 2.03 Billion INR | 42.25% |
| 2019 | 1.42 Billion INR | -0.58% |
| 2018 | 1.43 Billion INR | 12.52% |
| 2017 | 1.27 Billion INR | 17.99% |
| 2016 | 1.08 Billion INR | -7.26% |
| 2015 | 1.16 Billion INR | -7.93% |
| 2014 | 1.26 Billion INR | -1.81% |
| 2013 | 1.29 Billion INR | -5.7% |
| 2012 | 1.36 Billion INR | -22.64% |
| 2011 | 1.76 Billion INR | 9.73% |
| 2010 | 1.61 Billion INR | 16.62% |
| 2009 | 1.38 Billion INR | -3.16% |
| 2008 | 1.42 Billion INR | 8.58% |
| 2007 | 1.31 Billion INR | 86.94% |
| 2006 | 703.4 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 2.4 Billion INR | 9.36% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 2.37 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 2.4 Billion INR | 0.0% |
| 2022 Q4 | 2.19 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 2.08 Billion INR | 0.0% |
| 2022 FY | 2.19 Billion INR | 4.61% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.09 Billion INR | 3.28% |
| 2021 Q4 | 2.09 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.07 Billion INR | 0.0% |
| 2020 Q4 | 2.03 Billion INR | 0.0% |
| 2020 FY | 2.03 Billion INR | 42.25% |
| 2020 Q2 | 1.84 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 FY | 1.42 Billion INR | -0.58% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 1.48 Billion INR | 0.0% |
| 2019 Q4 | 1.42 Billion INR | 0.0% |
| 2018 FY | 1.43 Billion INR | 12.52% |
| 2018 Q4 | 1.43 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 1.27 Billion INR | 17.99% |
| 2016 FY | 1.08 Billion INR | -7.26% |
| 2015 FY | 1.16 Billion INR | -7.93% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q4 | 1.26 Billion INR | 0.0% |
| 2014 Q2 | 1.28 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 1.26 Billion INR | -1.81% |
| 2013 FY | 1.29 Billion INR | -5.7% |
| 2013 Q2 | 1.55 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 1.29 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 2.83 Billion INR | 0.0% |
| 2012 Q4 | 1.36 Billion INR | 0.0% |
| 2012 FY | 1.36 Billion INR | -22.64% |
| 2011 FY | 1.76 Billion INR | 9.73% |
| 2010 FY | 1.61 Billion INR | 16.62% |
| 2009 FY | 1.38 Billion INR | -3.16% |
| 2008 FY | 1.42 Billion INR | 8.58% |
| 2007 FY | 1.31 Billion INR | 86.94% |
| 2006 FY | 703.4 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | 65.417% |
| Ind-Swift Limited | 6.54 Billion INR | 63.32% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 68.625% |
| Sakar Healthcare Limited | 3.88 Billion INR | 38.233% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 99.467% |
| Innova Captab Limited | 13.2 Billion INR | 81.826% |
| Divi's Laboratories Limited | 154.7 Billion INR | 98.448% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 77.731% |
| Morepen Laboratories Limited | 12.93 Billion INR | 81.437% |
| Mankind Pharma Limited | 119.63 Billion INR | 97.993% |
| Sequent Scientific Limited | 15.4 Billion INR | 84.415% |
| Wanbury Limited | 3.43 Billion INR | 30.112% |
| Laurus Labs Limited | 83.87 Billion INR | 97.138% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 89.044% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 91.578% |
| Alembic Limited | 23.28 Billion INR | 89.691% |
| Hikal Limited | 24.87 Billion INR | 90.348% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 96.276% |
| Neuland Laboratories Limited | 18.32 Billion INR | 86.9% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 93.99% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 98.328% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 89.304% |
| Themis Medicare Limited | 5.66 Billion INR | 57.617% |
| RPG Life Sciences Limited | 5.12 Billion INR | 53.193% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 99.18% |
| Lupin Limited | 239.97 Billion INR | 99.0% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | 34.565% |
| Wockhardt Limited | 76.49 Billion INR | 96.862% |
| Vaishali Pharma Limited | 799.55 Million INR | -200.243% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 90.703% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -10.588% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 97.921% |
| FDC Limited | 24.68 Billion INR | 90.273% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 99.381% |
| Eris Lifesciences Limited | 70.48 Billion INR | 96.594% |
| Venus Remedies Limited | 6.26 Billion INR | 61.702% |
| ZIM Laboratories Limited | 4.46 Billion INR | 46.274% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 80.223% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -136.255% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 91.1% |
| Shilpa Medicare Limited | 30.93 Billion INR | 92.239% |
| Albert David Limited | 4.97 Billion INR | 51.794% |
| Ajanta Pharma Limited | 46.38 Billion INR | 94.824% |
| Hester Biosciences Limited | 6.62 Billion INR | 63.756% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 89.35% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 89.77% |
| Gufic Biosciences Limited | 10.92 Billion INR | 78.027% |
| Windlas Biotech Limited | 6.26 Billion INR | 61.664% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 69.779% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | 21.289% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | 28.001% |
| Granules India Limited | 55.2 Billion INR | 95.652% |
| Aarti Drugs Limited | 24.32 Billion INR | 90.131% |
| Bal Pharma Limited | 3.2 Billion INR | 25.072% |
| Alkem Laboratories Limited | 155.74 Billion INR | 98.459% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.719% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 65.72% |
| Medicamen Biotech Limited | 2.94 Billion INR | 18.491% |
| Unichem Laboratories Limited | 31.69 Billion INR | 92.426% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -62.553% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -409.872% |
| Valiant Laboratories Limited | 3.42 Billion INR | 29.947% |
| Orchid Pharma Limited | 15.53 Billion INR | 84.551% |
| Medico Remedies Limited | 961.95 Million INR | -149.556% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 79.396% |
| Ipca Laboratories Limited | 111.01 Billion INR | 97.838% |
| Brooks Laboratories Limited | 904.45 Million INR | -165.422% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | 40.676% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.709% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 98.406% |
| NATCO Pharma Limited | 69.06 Billion INR | 96.524% |
| Suven Life Sciences Limited | 2.84 Billion INR | 15.739% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -34.734% |
| Strides Pharma Science Limited | 58.39 Billion INR | 95.889% |
| Indoco Remedies Limited | 21.44 Billion INR | 88.807% |
| Alpa Laboratories Limited | 1.82 Billion INR | -31.453% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -59.12% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 53.39% |